Radiopharm Theranostics (RADX)

Executive Summary

Radiopharm Theranostics (RADX) is a clinical-stage biotechnology company at the forefront of precision oncology, developing a pipeline of first-in-class radiopharmaceuticals for both diagnostic imaging and targeted radiotherapy. Leveraging proprietary platforms based on antibodies, nanobodies, peptides, and small molecules, the company creates theranostic pairs that enable precise tumor detection and treatment. Its lead programs focus on high-unmet-need cancers, including those expressing B7H3, a promising target across multiple solid tumors. With a dual listing in Australia and the United States, Radiopharm is positioned to access global capital markets and collaborate with leading research institutions. The company's valuation of approximately $35 million reflects its early clinical stage, yet its innovative approach and diversified platform offer significant upside potential if clinical data prove positive. Radiopharm's pipeline is advancing through Phase 1 trials, with initial data readouts expected in the coming months. The company's strategy emphasizes rapid clinical validation and strategic partnerships to accelerate development and commercialization. Key upcoming catalysts include interim results from its lead B7H3-targeting program, which could de-risk the platform and support further pipeline expansion. The company also stands to benefit from broader industry trends in radiopharmaceuticals, including growing interest from large pharma in targeted radionuclide therapy. While still early-stage, Radiopharm's differentiated technology and focused execution make it a compelling opportunity in the evolving nuclear medicine landscape.

Upcoming Catalysts (preview)

• H2 2026Phase 1 interim data readout for B7H3-targeting radiopharmaceutical (RAD301)55% success
• Q1 2027IND or CTA clearance for next pipeline candidate (e.g., RAD204 or peptide-based asset)70% success
• H1 2027Strategic partnership or licensing deal for diagnostic or therapeutic asset50% success